Home Tags Adcetris

Tag: Adcetris

Health Canada Approves Brentuximab Vedotin + Chemotherapy in Frontline CD30-Expressing Peripheral...

Health Canada has approved the supplemental New Drug Submission that expands the use of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) in combination with CHP (cyclophosphamide,...

Supplemental Biologics License Application for Brentuximab Vedotin in Frontline Treatment of...

Seattle Genetics has submitted a supplemental Biologics License Application (BLA) for brentuximab vedotin (Adcetris®) to the U.S. Food and Drug Administration (FDA).The submission is...

Interim Results from Ongoing Studies of Brentuximab Vedotin + Nivolumab in...

Multiple presentations evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda*) across a broad range of Hodgkin lymphoma (HL) settings were presented at the 11th International Symposium...

Four Ways to Show Nonobviousness of ADC Inventions

As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.

Phase III ECHELON-1 Clinical Trial of Brentuximab Vedotin Meets Primary Endpoint...

Data from the Phase III ECHELON-1 clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics | Takeda) as part of a frontline combination chemotherapy regimen...

Long-term Data of Brentuximab Vedotin Redifines Treatment of Frontline Mature T-Cell...

Data highlighted at the 59th annual meeting of the American Society of Hematology (ASH) held in Atlanta, Georgia, December 9-12, 2017 shows final five-year...

Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...

This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...

Long-Term Data Continues to Support Development Strategy to Establish Brentuximab Vedotin...

Final data from the pivotal phase II trial with brentuximab vedotin (Adcetris®; Seattle Genetics/Takada)   in relapsed* or refractory** (r/r) systemic anaplastic large cell lymphoma (sALCL)...

Positive Phase III ECHELON-1 Trial Data Leads to FDA Breakthrough Therapy...

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with chemotherapy for the frontline...

U.S. FDA Grants Priority Review for Brentuximab Vedotin in Cutaneous T-Cell...

The United States Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the Phase...